A shot in the arm for Pharmaniaga

MIDF Research maintained its “buy’’ call with unchanged target price of 98 sen per share.

PETALING JAYA: Pharmaniaga Bhd’s initiative of supplying vaccines out of Malaysia will see its business prospering beyond the local sector.

Its long-term prospects also remains positive and with the group’s other strategies in providing access to its pharmaceuticals as well as increasing capacities and capabilities.